[CLSTR]
< Back to situations

[ORGANIZATION]

BioNTech SE

Featured in 6 tracked stories · first seen

Situations

[QUIET] [BUSINESS] [DE] [US] [SG]

BioNTech restructuring, oncology shift, revenue cut

11 clusters · 42 sources · last updated

Latest: BioNTech halts personalized mRNA colorectal cancer vaccine trial

In August 2026, BioNTech significantly reduced its full-year revenue outlook to €1.6–1.9 billion, down from a previous target of €2.0–2.3 billion, citing declining COVID-19 vaccine demand and lost milestone payments. The

Also covered in